Public annual accounts

ImmunoSource financials

Name: ImmunoSource financials
Creator: Upswitch
License: https://www.upswitch.app/terms-and-conditions

A multi-period view of the public annual-account figures reported for ImmunoSource, with comparable measures and links to available source documents.

Company overview

Registry number

0451125125

Fiscal coverage

2024–2025

Public sources

cbso_bulk

Data updated

Jul 28, 2026

Financial evidence

Latest movements for ImmunoSource

2025 versus 2024

Operating line: €88,294
EBITDA: €86,181
Total assets: €1,424,796
Equity: €1,398,557

EBITDA margin +97.6% · Equity ratio +98.2%

Multi-year filings

Filed annual accounts by fiscal year

Public regulator-filed figures across 2 years.

Source: NBB/CBSO

Fiscal year	Gross margin	EBITDA	Total assets	Equity	Filing
202531 Jul 2025	€88,294	€86,181	€1,424,796	€1,398,557	-
202431 Jul 2024	€128,859	€126,467	€1,487,556	€1,425,818	-

Gross margin line from gross margin (abbreviated schema). This is not reported turnover, so it is not used as a public valuation base.EBITDA basis: operating profit plus full add-backs.

Figures reproduce public filings and may use country-specific accounting definitions. They are not audited by Upswitch.

Public company datasets

Explore the underlying reports

Valuation

2 valuation checkpoints · 2024 to 2025 · Method family

Open report